OG-L002 is a selective inhibitor of LSD1 with IC50 of 20 nM.

GSK2879552 2HCl is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.

ORY-1001 is a selective inhibitor of lysine-specific demethylase LSD1/KDM1A with IC50 of < 20 nM.

SP-2509 is a histone demethylase LSD1 (KDM1A) antagonist with IC50 of 13 nM.

CC-90011 is a potent and orally active LSD1 inhibitor. It is in phase I clinical study of CC-90011 in patients (pts) with advanced unresectable solid tumors and R/R NHL.

T-3775440 is an LSD1 inhibitor which inhibits SCLC cell proliferation by disrupting LDS1 interactions with SNAG domain proteins INSM1 and GFI1B.